Geoffrey Clapp Biography and Net Worth

Insider of Progyny

Geoffrey Clapp is the Chief Product Officer at Progyny, leading the strategy and development roadmap for Progyny’s expanding portfolio of high-impact, scalable solutions designed to improve access to family building and women’s health care. With deep experience building innovative platforms that center on patients and providers, Geoffrey helps drive Progyny’s product evolution with the same level of clinical excellence, personalization, accessibility, and superior outcomes the company is known for.

Prior to joining Progyny, Geoffrey served as Senior Vice President and Head of Strategy at Optum Health Solutions, where he reimagined and rebuilt core products in renal care and organ transplant, driving significant earnings growth and improved outcomes. Earlier in his career, he co-founded a market-leading remote patient monitoring company—acquired by Bosch—and has led product and engineering teams at several healthcare startups and organizations globally. He is a recipient of Business Week’s Best Product award for his work in chronic disease management and is known for bridging clinical insight with cutting-edge technology.

Geoffrey holds a Bachelor of Arts from Goucher College in Computer Science and Cognitive Psychology.

What is Geoffrey Clapp's net worth?: The estimated net worth of Geoffrey Clapp is at least $1.53 million as of June 2nd, 2026. Clapp owns 59,117 shares of Progyny stock worth more than $1,530,598 as of June 4th. This net worth evaluation does not reflect any other assets that Clapp may own. Learn More about Geoffrey Clapp's net worth.
How do I contact Geoffrey Clapp?: The corporate mailing address for Clapp and other Progyny executives is 1359 BROADWAY, NEW YORK NY, 10018. Progyny can also be reached via phone at 212-888-3124 and via email at [email protected]. Learn More on Geoffrey Clapp's contact information.
Has Geoffrey Clapp been buying or selling shares of Progyny?: During the last ninety days, Geoffrey Clapp has sold $39,137.40 of Progyny stock. Most recently, Geoffrey Clapp sold 1,530 shares of the business's stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $25.58, for a transaction totalling $39,137.40. Following the completion of the sale, the insider now directly owns 59,117 shares of the company's stock, valued at $1,512,212.86. Learn More on Geoffrey Clapp's trading history.
Who are Progyny's active insiders?: Progyny's insider roster includes Peter Anevski (COO), Jennifer Bealer (EVP), Geoffrey Clapp (Insider), Melissa Cummings (COO), Kevin Gordon (Director), Lisa Greenbaum (EVP), Mark Livingston (CEO), Norman Payson (Director), David Schlanger (Executive Chairman), Cheryl Scott (Director), Michael Sturmer (President), and Allison Swartz (General Counsel). Learn More on Progyny's active insiders.
Are insiders buying or selling shares of Progyny?: In the last twelve months, Progyny insiders bought shares 1 times. They purchased a total of 79,500 shares worth more than $1,931,055.00. In the last twelve months, insiders at the sold shares 17 times. They sold a total of 72,672 shares worth more than $1,760,223.48. The most recent insider tranaction occured on June, 2nd when CFO Mark S Livingston sold 279 shares worth more than $7,309.80. Insiders at Progyny own 9.9% of the company. Learn More about insider trades at Progyny.
Information on this page was last updated on 6/2/2026.

Geoffrey Clapp Insider Trading History at Progyny

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/2/2026	Sell	1,530	$25.58	$39,137.40	59,117

Geoffrey Clapp Buying and Selling Activity at Progyny

Progyny Company Overview

Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides assistance service programs where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.

Today's Range

Now: $25.49

$25.08

$25.99

50 Day Range

MA: $20.27

$16.30

$26.20

2 Week Range

Now: $25.49

$16.10

$28.75

Volume

690,042 shs

Average Volume

1,553,495 shs

Market Capitalization

$2.00 billion

P/E Ratio

33.10

Dividend Yield

N/A

Beta

1.03